Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Barrow

Showing results (21-30 of 82) with videos related to

Pageof 9
Sort By:
Infection and Immunity|September 1, 1983
Postphagocytic detection of glycopeptidolipids associated with the superficial L1 layer of Mycobacterium intracellulareM J Tereletsky, W W Barrow
Infection and Immunity|May 1, 1982
Immunogenicity of type-specific C-mycoside glycopeptidolipids of mycobacteriaW W Barrow, P J Brennan
Advances in Experimental Medicine and Biology|January 1, 1988
Decreased mitogenic response of murine spleen cells following intraperitoneal injection of serovar-specific glycopeptidolipid antigens from the Mycobacterium avium complexL C Hooper, W W Barrow
Research in Microbiology|June 1, 1991
Inhibition of glycopeptidolipid synthesis resulting from treatment of Mycobacterium avium with 2-deoxy-D-glucoseE L Wright, W W Barrow
American Family Physician|September 29, 1998
Heat-related illnessesM W Barrow, K A Clark
Drug Delivery|September 17, 2004
Sustained release characteristics of rifampin-loaded microsphere formulations in nonhuman primatesDebra Quenelle, Gary A Winchester, Jay K Staas, et al.
Clinical and Experimental Immunology|July 1, 1993
Comparative effects of Mycobacterium avium glycopeptidolipid and lipopeptide fragment on the function and ultrastructure of mononuclear cellsM Pourshafie, Q Ayub, W W Barrow
The Journal of Antimicrobial Chemotherapy|March 3, 1999
Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductaseW J Suling, R C Reynolds, E W Barrow, et al.
Antimicrobial Agents and Chemotherapy|July 8, 2010
Inhibition of antibiotic-resistant Staphylococcus aureus by the broad-spectrum dihydrofolate reductase inhibitor RAB1C R Bourne, E W Barrow, R A Bunce, et al.
Antimicrobial Agents and Chemotherapy|April 15, 2009
Crystal structure of Bacillus anthracis dihydrofolate reductase with the dihydrophthalazine-based trimethoprim derivative RAB1 provides a structural explanation of potency and selectivityChristina R Bourne, Richard A Bunce, Philip C Bourne, et al.
Pageof 9

Showing results (21-30 of 82) with videos related to

Sort By:
Pageof 9
Infection and Immunity|September 1, 1983
Postphagocytic detection of glycopeptidolipids associated with the superficial L1 layer of Mycobacterium intracellulareM J Tereletsky, W W Barrow
Infection and Immunity|May 1, 1982
Immunogenicity of type-specific C-mycoside glycopeptidolipids of mycobacteriaW W Barrow, P J Brennan
Advances in Experimental Medicine and Biology|January 1, 1988
Decreased mitogenic response of murine spleen cells following intraperitoneal injection of serovar-specific glycopeptidolipid antigens from the Mycobacterium avium complexL C Hooper, W W Barrow
Research in Microbiology|June 1, 1991
Inhibition of glycopeptidolipid synthesis resulting from treatment of Mycobacterium avium with 2-deoxy-D-glucoseE L Wright, W W Barrow
American Family Physician|September 29, 1998
Heat-related illnessesM W Barrow, K A Clark
Drug Delivery|September 17, 2004
Sustained release characteristics of rifampin-loaded microsphere formulations in nonhuman primatesDebra Quenelle, Gary A Winchester, Jay K Staas, et al.
Clinical and Experimental Immunology|July 1, 1993
Comparative effects of Mycobacterium avium glycopeptidolipid and lipopeptide fragment on the function and ultrastructure of mononuclear cellsM Pourshafie, Q Ayub, W W Barrow
The Journal of Antimicrobial Chemotherapy|March 3, 1999
Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductaseW J Suling, R C Reynolds, E W Barrow, et al.
Antimicrobial Agents and Chemotherapy|July 8, 2010
Inhibition of antibiotic-resistant Staphylococcus aureus by the broad-spectrum dihydrofolate reductase inhibitor RAB1C R Bourne, E W Barrow, R A Bunce, et al.
Antimicrobial Agents and Chemotherapy|April 15, 2009
Crystal structure of Bacillus anthracis dihydrofolate reductase with the dihydrophthalazine-based trimethoprim derivative RAB1 provides a structural explanation of potency and selectivityChristina R Bourne, Richard A Bunce, Philip C Bourne, et al.
Pageof 9